Perspectives on US health care systems

October 26, 2022

Written by



Dan Shoenholz Partner **EY-Parthenon** Ernst & Young LLP




Dave Davies Partner **EY-Parthenon** Ernst & Young LLP



Senior Director EY-Parthenon Ernst & Young LLP



With 8,200 professionals and 900 partners across the globe, EY-Parthenon is one of the largest strategy consultancies, bringing deep sector experience to clients






We work with 92% of Private Equity International's top 25 global private equity firms; our global PE network is made up of more than 11k professionals

	EY work across private equity	
Global PE leaders	92% EY works with 92% of Private Equity International's top 25 global private equity firms	~4,500 diligence projects
Experienced team	> 20 years EY has been working closely with private equity clients for more than 20 years	200 4700 4100 2019-05-09
Dedicated professionals	> 11,000 The EY Global Private Equity network includes more than 11,000 professionals worldwide	Working with top-tier PE funds and portfolio companies



EY-Parthenon had a global private equity practice with dedicated team members across continents serving 200+ private equity firm clients




We worked with the vast majority of the global top 20 private equity firms last year, along with more than 200 middle market firms



Significant deal activity in 2021, followed by continued activity through 1H2022; EY-P engaged in deal activity across the sector, with emphasis on HCIT

Health care PE deals and EY-Parthenon engagements (2021-2022)








Life sciences deal volume was also active in 2021, with continued activity so far in 2022; MedTech devices/diagnostics has seen growing deal volume 2022

Life sciences PE deals and EY-Parthenon engagements (2021-2022)

Life sciences PE deals by subsector (2021-2022)




Agenda

- Macro trends
- Investment themes



Federal public health programs and supplemental COVID-19 relief funds accounted for the vast majority of increase in national health expenditures from 2019 to 2020

Change in US national health expenditures by source of spend (2019-2020)



1. Includes COVID-19 related federal public health spending

2. Includes PPP loans and Provider Relief Fund


3. Includes state public health programs; Medicare, and other non-federal third-party programs

Source: CMS; Health Affairs



Medicare/private insurance are key contributors to increased NHE from 2020 to 2021; a significant decrease in federal program and COVID-19 relief funding is expected

Change in US national health expenditures by source of spend (2020-2021P)




2. Includes PPP loans and Provider Relief Fund

3. Includes state public health programs and other non-federal third-party programs

Source: CMS; Health Affairs

Total real consumer spending on health is close to pre-pandemic levels, but is still almost 5% below its pre-pandemic trend


Total real spending on health (services + goods) vs. pre-COVID-19 trend¹ (January 2017-June 2022)





Health care price inflation is expected to become a larger contributor to the nominal consumer health care spending growth outlook once again

Annual % change of real and nominal health care spending (2007-2026)






Demand for health care and social assistance workers has not only risen rapidly, but the gap relative to total private sector job openings has widened

Comparison of health care job openings to total private sector (2010-2022)








Average hourly earnings for health care services employees continue to rise, with nursing home employees seeing the greatest upward wage pressure

Change in average hourly earnings by health care setting

Average hourly employee earnings year-over-year % change in health care services categories Jan 2020-Jun 2022, seasonally adjusted





Amid labor supply constraints, there are several opportunities in care delivery, practice management, and employee experience, education and retention

Labor supply: opportunities within care delivery, practice management, employee experience, education and retention

	Opportunity	Description and rationale				
	 Telemedicine and virtual care 	 Increase efficiency of patient visits and mitigate physician burnout 				
	 Transition of care technologies 	 Facilitate data-driven transitions of care to improve outcomes for high-risk populations 				
Care delivery	 Digital therapeutics 	 Deliver digital interventions to prevent, manage and treat conditions 				
	 Social determinants of health 	 Prevent unnecessary care by addressing patient's needs earlier 				
	 Remote patient monitoring 	 Prevent high utilization by implementing remote patient monitoring technologies 				
	 Pharmacy automation technologies 	 Reduce nurse time spent reviewing and dispensing medications 				
	 Efficiency saving HCIT (e.g., AI-driven scheduling, intelligent credentialing) 	 Provide data-driven approaches to optimize processes such as staffing and credentialing at the unit/enterprise levels 				
Practice management	 Tech-enabled medical staffing 	 Deploy providers within short timeframes and consolidate back-office needs 				
	 Scaled physician practice management 	 Develop platform practices with sufficient infrastructure and revenue to rollup 				
	 Digital employee onboarding platforms 	 Provide onboarding experiences that drive engagement, satisfaction, retention 				
Employee experience,	 Ongoing training and upskilling platforms 	 Offer virtual training/upskilling for providers to practice at full extent of licenses 				
education and retention	 Omnichannel employee feedback 	 Collect structured employee feedback to proactively address pain points 				
	 Physician extender education 	 Support continued growth in supply of nurse practitioners and physician assistants 				



Agenda

- Macro trends
- Investment themes



Recent investment themes have focused on value within providers and payers while focusing on ... in pharma services

Recent trends in private equity investment in health care

Value

An increased focus has been given to value creation and the sources of value within providers, both physician practices and multisite providers, and provider services

Behavioral and physical health

Health care organizations have recognized the impact that behavioral and mental health has on physical health and are pursuing integrated strategies of patient care

Payer services

A continued focus on value combined with the broader macroeconomic landscape has increased interest in payer services, including member engagement, care navigation and population health management

Pharma services

Biopharma organizations continue to emphasize spend on outsourced services, particularly within the commercialization process as the product pipeline grows and complexity in bringing drugs to market increases




Specialty deep dives: orthopedics

Private equity investment in orthopedics has accelerated in recent years with more than 20-25 investments in 2021 and 2022


Focus on value Behavioral and physical health Payer services Pharma services

Orthopedic physician practice management





Weighted average total cost of care for major orthopedic surgery¹ (2021)




- The transition to ASC-based orthopedic procedures represents significant cost savings with hospital-based procedures costings 1.8x-2.2x as much
- Value-based contracting opportunity is still developing, but represents opportunity to be preferred provider with payers



The value chain for risk-bearing primary care clinics includes a variety of different services

Risk-bearing primary care value chain and services






Though ~25% of Americans have received a BH diagnosis, BH accounts for more than half of health care spend

Impact of BH/MH diagnoses on physical health

Distribution of total health care costs among segments of the US population (2017)



Length of hospital stay by behavioral health diagnosis (Massachusetts, 2020)

5.3

Substance

use

disorders

only

4.3

No

MH/SUD

diagnoses

Behavioral and physical health Payer services Pharma services

Focus on value

EY-Parthenon perspectives

- The share of US health care spending attributable to behavioral health patients signals a need to address BH conditions at the beginning of the care continuum
- As physicians increasingly shift to riskbearing models, the onus falls on primary care doctors and other lower acuity providers to effectively triage BH patients to avoid downstream costs
- To better meet the needs of BH patients, investors have increasingly targeted businesses that include:
 - Behavioral health platforms offering a comprehensive suite of BH services to drive value-based care
- Patient-facing technological tools deployed at the point of diagnosis and that serve as continuity of care enablers



Increasing consumerization of behavioral health care has led to innovation in treatment technologies and increased investment

Recent investments and example vendors by BH subsegment


Treatment area		Example vendors	Recent investment		
Substance abuse		DynamiCare Pivot OPTUM® Quit For Life® Workit Health PESET QuitGenius	 In June 2021, Pear Therapeutics (reSET and Somryst) agreed to go public through a merger with Thimble Point Acquisition Corp in a ~\$1.6b SPAC deal In October 2021 Workit Health raised \$118m of series C venture funding 		
Mental health	Self-directed care	h Image: Color big Health Image: Section Big Health Image: Somryst ginger iPrevail Meru Health	 In March 2021, Happify raised \$73m Series D venture funding In August 2021 Headspace entered into an agreement to acquire Ginger that values the combined company at ~\$3b In September 2021, Meru Health raised \$38m series B financing 		
	Online therapy	betterhelp 7 CUPS Able To	 In 2020, AbleTo was acquired by Optum for \$470m 		
	Employee assistance programs	Modern Health Spring health Olimeade	 In September 2021, Spring Health received \$190m in Series C funding to serve the global workforce and build out a family of mental health solutions 		



PHM and member engagement tools have considerable untapped potential to bring payers closer to members and bend the cost curve

Focus on value Behavioral and physical health **Payer services** Pharma services

Payer solutions by potential impact and maturity of solutions



1: Significant variation in potential whitespace exists between legacy payment integrity and emerging cost containment solutions Source: CMG; Fierce Healthcare; Forbes; EY-Parthenon analysis




Member engagement solutions vary in their level of digital enablement; the top solutions are digitally enabled and offer concierge-level service

Payer services

Pharma services

Overview of member engagement solutions



Landscape of companies offering member engagement solutions

- Comprehensive concierge solutions are patient-centric organizations that vary in their digital capabilities due to different levels of emphasis and investment
- Developing guidance solutions have relatively high digital integration with their core solutions, but limited capabilities in customer-centric concierge services
- Unlike dedicated advocacy vendors (e.g., Accolade, Quantum Health), these vendors have well-known offerings that are not advocacy-specific but are beginning to expand into the advocacy space
- Most major carriers are developing advocacy solutions to compete with dedicated providers, though some offerings are considered basic relative to dedicated offerings
- "Health plan guidance solutions have access to patient claim data and emphasize digital enablement to drive efficiency, but don't provide a high touch service experience to patients"
- "Carriers are trying to keep from being carved out; they'll need to expand those operations to create an equal playing field"
- "Health plan solutions have the least differentiation between them"

Comprehensive concierge solutions that are highly digital enabled will win in the member engagement space



A drug's lifecycle spans four key processes; the commercialization Behavioral and physical health Payer services effort is responsible for maximizing the value of a new drug in market **Pharma services ILLUSTRATIVE** Drug lifecycle **Clinical development Preclinical development** Launch **In-market** Discovery Translational **Clinical operations** research sciences **Regulatory affairs** R&D Compliance Clinical supply manufacturing Medical strategy 2 Medical Medical communications Field/medical science liaisons Brand strategy Market access Commercialization RWE/RWD Sales Trade and distribution IT **Corporate**/ HR operations Finance Corporate development Out of scope In-scope



Focus on value

Investment themes

Functional leaders seek to outsource capabilities to commercialization vendors that solve for qualitative and/or quantitative pain points

Payer services

Pharma services

Functional use cases

		Brand strategy/NPP	Market access/ HEOR	Insights and analytics	Medical affairs	US brand marketing	Patient access	Sales	Trade and distribution
Over need	view of s	 High level market data and research to inform product launch and pipeline dev. 	 Real-world data (e.g., EHR) and market research to support payer value prop./ economic and health outcomes 	 Datasets and third-party analytical tools to support a range of business functions 	 Physician research and prescriber/ patient data to aid KOL engagement 	 Omnichannel optimization, market research, market data (e.g., share, customer satisfaction) 	 Consumer research and reimbursement data to measure patient patterns 	 Dashboards to measure a range of KPIs, (e.g., sales by customer type, discounts offered, etc.) 	 Data aggregation across channel partners to gain insight into budget and downstream inventory
	Illustrative uses of vendor by function							<u>.</u>	
	Consulting/ marketing agencies	Understand market landscape	Understand competitive landscape	Measure customer sentiment (ATU)	Inform KOL engagement	Develop campaigns and advertising strategy	Develop reimbursement journey	Develop territory alignment	Perform channel analysis
Vendo	Data providers	Gather market data (e.g., competitor market shares)	Analyze competitive pricing	Inform market research findings	Understand existing clinical results	Provide deidentified EHR records to inform targeting	Compile patient outcome data		Offer retail data to inform distribution strategy
	Analytical tools and services	Understand patient flow	Monitor formulary positions	Inform market research findings	Identify KOLs	Analyze ROI of specific campaigns to optimize mix		Develop sales dashboards (e.g., performance predictions)	Support inventory analytics (e.g., demand planning optimization)
	Workflow/ infrastructure solutions					Programmatic ad purchasing	Administer patient assistance	Align incentive compensation	Contract and payment processing automation
		High Low		Often use thir	d-party vendor	Sometimes use	third-party vendor	Seldom use thi	rd-party vendor



EY | Building a better working world

EY exists to build a better working world, helping to create long-term value for clients, people and society and build trust in the capital markets.

Enabled by data and technology, diverse EY teams in over 150 countries provide trust through assurance and help clients grow, transform and operate.

Working across assurance, consulting, law, strategy, tax and transactions, EY teams ask better questions to find new answers for the complex issues facing our world today. EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. Information about how EY collects and uses personal data and a description of the rights individuals have under data protection legislation are available via ey.com/privacy. EY member firms do not practice law where prohibited by local laws. For more information about our organization, please visit ey.com.

About EY-Parthenon

EY-Parthenon teams work with clients to navigate complexity by helping them to reimagine their eco-systems, reshape their portfolios and reinvent themselves for a better future. With global connectivity and scale, EY-Parthenon teams focus on Strategy Realized – helping CEOs design and deliver strategies to better manage challenges while maximizing opportunities as they look to transform their businesses. From idea to implementation, EY-Parthenon teams help organizations to build a better working world by fostering long-term value. EY-Parthenon is a brand under which a number of EY member firms across the globe provide strategy consulting services. For more information, please visit ey.com/parthenon.

Ernst & Young LLP is a client-serving member firm of Ernst & Young Global Limited operating in the US.

© 2022 Ernst & Young LLP. All Rights Reserved.

2210-4099080 ED None

This material has been prepared for general informational purposes only and is not intended to be relied upon as accounting, tax, legal or other professional advice. Please refer to your advisors for specific advice.

ey.com